Related Experiment Video
Updated: Dec 21, 2025
06:58
A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study
Published on: November 6, 2015
10.1K
Boston Type 1 Keratoprosthesis: Updated Perspectives
Manachai Nonpassopon1,2, Muanploy Niparugs2,3, Maria Soledad Cortina2
1Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clinical Ophthalmology (Auckland, N.Z.)
|May 20, 2020
Summary
Boston type 1 keratoprosthesis (BKPro) offers favorable intermediate to long-term visual outcomes and retention rates. However, patients with autoimmune diseases or cicatrizing conditions face higher complication risks requiring further management.
Area of Science:
- Ophthalmology
- Biomaterials Science
Background:
- Boston type 1 keratoprosthesis (BKPro) use has increased globally.
- It's now a viable option for poor-prognosis corneal transplant cases, not just a last resort.
- Approved in 1992 for severe bilateral corneal blindness from transplant failure, indications have expanded.
Purpose of the Study:
- To review intermediate to long-term outcomes of Boston type 1 keratoprosthesis (BKPro) implantation.
- To assess visual outcomes and device retention rates with an average follow-up of at least two years.
Main Methods:
- Systematic review of publications with a minimum two-year average follow-up.
- Analysis of visual outcomes and complication rates associated with BKPro.
Main Results:
- Intermediate to long-term visual outcomes and retention rates for BKPro are generally favorable.
- Advances in device design and patient management have improved outcomes and reduced complications.
- Autoimmune diseases and cicatrizing conditions are associated with a higher incidence of postoperative complications.
Conclusions:
- Boston type 1 keratoprosthesis (BKPro) demonstrates favorable intermediate to long-term effectiveness in restoring vision.
- Careful patient selection and management are crucial, especially for those with autoimmune or cicatrizing conditions.
- Further research is needed to address the higher complication rates in specific patient groups.
